How to get from antiplatelet to antithrombotic treatment

American Journal of Therapeutics

Volumn 8, Issue 6, 2001, Pages 443-449

  Eisert, W G ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Antiplatelet therapy; Antithrombotic therapy; Clopidogrel; Dipyridamol; Tissue perfusion

Indexed keywords

ANTITHROMBOCYTIC AGENT; FIBRINOLYTIC AGENT;

CEREBROVASCULAR ACCIDENT; DRUG COMBINATION; DRUG EFFECT; HUMAN; METABOLISM; REVIEW; THROMBOCYTE; THROMBOCYTE ACTIVATION;

BLOOD PLATELETS; CEREBROVASCULAR ACCIDENT; DRUG THERAPY, COMBINATION; FIBRINOLYTIC AGENTS; HUMANS; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS;

EID: 0035515747     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045391-200111000-00009     Document Type: Article

References (4)

1. Born GVR, Cross MJ: Inhibition of the aggregation of blood platelets by substances related to adenosine diphosphate. J Physiol 1963;166:29P-30P.
2. Stein B, Fuster V, Israel DH, et al: Platelet inhibitor agents in cardiovascular disease: an update. J Am Coll Cardiol 1989;14:813-836.
3. Horie S, Yamada M, Satoh M, et al: The potent inhibition of vapiprost, a novel thromboxane A2 receptor antagonist, on the secondary aggregation and ATP release of human platelets. Biol Pharm Bull 1997;20:625-631.
4. Hacker RW, Torka M, Yukseltan I, et al: Reduction of the vain graft occlusion rate after coronary artery bypass surgery by treatment with a thromboxane receptor antagonist. Z Kardiol 1989;78(Suppl):48S-49S.